| Short bowel syndrome: the role of GLP-2 on improving outcome. | |
| | |
MedLine Citation:
|
PMID: 19474717 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: The medical management of short bowel syndrome frequently requires lifelong parenteral nutrition. Methods of increasing intestinal absorption and reducing parenteral nutrition dependence, by improving postresection intestinal adaptation, are increasingly being explored. Glucagon-like peptide-2 (GLP-2) is an important intestinotrophic growth factor and mediator of intestinal adaptation. This review summarizes our current understanding of GLP-2 physiology and provides an update on clinical trials in short bowel syndrome and related conditions. RECENT FINDINGS: There is growing understanding how the effects of GLP-2 are mediated by downstream effectors such as insulin-like growth factor-1. In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analogue teduglutide (Gattex) are effective in improving fluid absorption. A recent multicentre, placebo-controlled study demonstrates that this can translate into meaningful reductions in parenteral nutrition requirements. Treatment dose and timing of treatment initiation might influence the mucosal growth response. Most of the small intestine has to be preserved to facilitate the previously documented benefits of GLP-2 on bone metabolism. Therapeutic uses of GLP-2 in other gastrointestinal conditions are being explored. GLP-2 treatment appears well tolerated, although concerns about the long-term use of this growth-promoting agent remain. SUMMARY: GLP-2 therapy holds promise as an adjuvant treatment modality for short bowel syndrome and other gastrointestinal disorders. |
| | |
Authors:
|
Katharina Wallis; Julian R F Walters; Simon Gabe |
Related Documents
:
|
11424137 - Chest wall hamartoma with wiedemann-beckwith syndrome: clinical report and brief review... 890997 - Male pseudohermaphroditism due to partial end-organ insensitivity to androgens. 710857 - Experimental evidence for vasoactive intestinal peptide as the cause of the watery diar... 15672077 - Endoscopic resection of peutz-jeghers polyps throughout the small intestine at double-b... 19810637 - Anterior spinal artery syndrome in a girl with down syndrome: case report and literatur... 6225657 - Pathophysiology of the ciliary motility syndromes. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Current opinion in clinical nutrition and metabolic care Volume: 12 ISSN: 1535-3885 ISO Abbreviation: Curr Opin Clin Nutr Metab Care Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-08-04 Completed Date: 2009-10-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9804399 Medline TA: Curr Opin Clin Nutr Metab Care Country: England |
Other Details:
|
Languages: eng Pagination: 526-32 Citation Subset: IM |
Affiliation:
|
Division of Medicine, Imperial College Healthcare, Hammersmith Hospital, London, UK. katharina.wallis@imperial.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adaptation, Physiological
/
drug effects*,
physiology Glucagon-Like Peptide 2 / physiology*, therapeutic use* Humans Intestinal Absorption / drug effects, physiology Intestinal Mucosa / drug effects, growth & development, pathology Nutritional Requirements Parenteral Nutrition Peptides Short Bowel Syndrome / drug therapy*, physiopathology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Glucagon-Like Peptide 2; 0/Peptides; 0/teduglutide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of dietary mutagens in cancer and atherosclerosis.
Next Document: Nutrition in heart failure: an update.